114 results on '"Yun Jeong Song"'
Search Results
2. Prediction of Compression Ratio for Transform-based Lossy Compression in Time-series Datasets.
- Author
-
Aekyung Moon, Juyoung Park, and Yun Jeong Song
- Published
- 2022
- Full Text
- View/download PDF
3. Anomaly Detection in Edge Nodes using Sparsity Profile.
- Author
-
Aekyeung Moon, Xiaoyan Zhuo, Jialing Zhang, Seung Woo Son 0001, and Yun Jeong Song
- Published
- 2020
- Full Text
- View/download PDF
4. Understanding Bit-Error Trade-off of Transform-based Lossy Compression on Electrocardiogram Signals.
- Author
-
Aekyeung Moon, Seung Woo Son 0001, Jiuk Jung, and Yun Jeong Song
- Published
- 2020
- Full Text
- View/download PDF
5. Transform-based Lossy Compression for HPC Big Datasets.
- Author
-
Aekyung Moon, Juyoung Park, and Yun Jeong Song
- Published
- 2021
- Full Text
- View/download PDF
6. Circulating TNF-like protein 1A (TL1A) is elevated early in rheumatoid arthritis and depends on TNF
- Author
-
Yun-Jeong Song, In Ah. Choi, Françoise Meylan, M. Kristen Demoruelle, Taylor Farley, Arianne C. Richard, Eric Hawley, John Botson, Yoo Jin Hong, Eun Young Lee, Sabina R. Mian, Bartlett C. Hamilton, Geoffrey M. Thiele, Ted R. Mikuls, Naveen Gara, Chris D. Ward, Sarah Lamberth, Kevin D. Deane, Theo Heller, Michael M. Ward, David M. Lee, Thi-Sau Migone, William Stohl, James R. O’Dell, Jill M. Norris, V. Michael Holers, Peter Gregersen, Yeong-Wook Song, and Richard M. Siegel
- Subjects
Rheumatoid arthritis ,Cytokines ,Tumor necrosis factor-like cytokine 1A ,TNFSF15 ,Collagen-induced arthritis ,Diseases of the musculoskeletal system ,RC925-935 - Abstract
Abstract Background The tumor necrosis factor (TNF) superfamily cytokine TNF-like protein 1A (TL1A) and its receptor DR3 are essential for diverse animal models of autoimmune disease and may be pathogenic in rheumatoid arthritis (RA). However, the relationship of TL1A to disease duration, activity, and response to anti-TNF and other therapies in RA is not clear. Methods We measured soluble TL1A in synovial fluid (SF), serum, or plasma from RA first-degree relatives (FDRs) and in early RA and established disease. We measured the effects of anti-TNF and methotrexate (MTX) therapy on circulating TL1A from multiple independent RA treatment trials. We also determined the ability of a blocking anti-TL1A antibody to inhibit clinical disease and articular bone destruction in the murine collagen-induced arthritis (CIA) model of human RA. Results Soluble TL1A was specifically elevated in the blood and SF of patients with RA compared to patients with other diseases and was elevated early in disease and in at-risk anti-cyclic citrullinated peptide (CCP) (+) first-degree relatives (FDRs). Therapeutic TNF inhibition reduced serum TL1A in both responders and non-responders, whereas TL1A declined following MTX treatment only in responders. In murine CIA, TL1A blockade was clinically efficacious and reduced bone erosions. Conclusions TL1A is specifically elevated in RA from early in the disease course and in at-risk FDRs. The decline in TL1A after TNF blockade suggests that TL1A levels may be a useful biomarker for TNF activity in RA. These results support the further investigation of the relationship between TL1A and TNF and TL1A blockade as a potential therapeutic strategy in RA.
- Published
- 2020
- Full Text
- View/download PDF
7. A Study on the Current Status of Designation and Improvement Plan of the Focused Landscape Management Area
- Author
-
Yun Jeong Song, Kyung Jae Lee, Jae-Sung Bang, and Sang Min Lee
- Subjects
General Earth and Planetary Sciences ,General Environmental Science - Published
- 2022
8. Sex and Gender Differences in Overlap Syndrome of Functional Gastrointestinal Disorder and Effect of Genetic Polymorphisms in South Korea: A Long-term Follow-up Study
- Author
-
Ju Yup Lee, Nayoung Kim, Ji Hyun Park, Jeong Eun Yu, Yun Jeong Song, Jung Won Yoon, and Dong Ho Lee
- Subjects
Male ,Irritable bowel syndrome ,Gastroenterology ,Original Article ,Female ,Neurology (clinical) ,Dyspepsia ,Polymorphism - Abstract
Background/Aims Overlap functional gastrointestinal disorder (FGID) is associated with more severe gastrointestinal symptoms and lower quality of life. The aim of this study is to evaluate clinical features of non-erosive reflux disease (NERD), functional dyspepsia, irritable bowel syndrome, their overlap in terms of sex and gender, and to assess the risk factors, including genetic polymorphisms. Methods A total of 494 FGIDs and 239 controls were prospectively enrolled between 2004 and 2020. FGIDs were diagnosed based on the Rome III criteria and symptoms were evaluated using a questionnaire. Follow-up questionnaires were conducted to determine the change of symptoms during the 75.8-month mean observation period. Risk factors including genetic polymorphisms in neurotransmitter receptor (SLC6A4 5-HTTLPR, GNB3, ADRA2A, CCKAR, and TRPV1) and cytokine (TNFA and IL10) genes. Results NERD was more prevalent in men, and functional dyspepsia in women. Overlap FGIDs (n = 239) were more prevalent than non-overlap FGIDs (n = 255) in women (P = 0.019). Anxiety and depression scores were higher in the overlaps (P = 0.012 and P < 0.001, respectively). Symptoms were more frequent and severe in the overlap FGIDs than in the non-overlaps (P < 0.001). During follow-up, symptoms progressed more frequently in the overlap FGIDs, especially in patients with the L/S genotype of SLC6A4 5-HTTLPR and anxiety/depression. Conclusions Overlap FGID patients need attention given their association with anxiety/depression and more severe symptoms, especially in women. Genetic polymorphisms also may be associated with certain symptoms of overlap FGIDs.
- Published
- 2022
9. Hybrid DMB services based on mobile broadcast/communication converged networks.
- Author
-
Byungjun Bae, Joungil Yun, Hyung-Kou Cho, Yun-Jeong Song, and Namho Hur
- Published
- 2013
- Full Text
- View/download PDF
10. Performance Evaluation of DAB, DAB+ and T-DMB Audio: Field Trial.
- Author
-
Myung-Sun Baek, Yonghoon Lee, So Ra Park, Geon Kim, Bo-Mi Lim, Yun-Jeong Song, and Yong-Tae Lee
- Published
- 2011
- Full Text
- View/download PDF
11. The implementation of Advanced T-DMB based on hierarchical modulation.
- Author
-
Youngsu Kim, JaeHwui Bae 0001, Jong Soo Lim, Yun Jeong Song, and Soo In Lee
- Published
- 2009
- Full Text
- View/download PDF
12. A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors
- Author
-
Ji Hye Lee, Yeon Hee Park, Young Suk Park, Won Ki Kang, Jeeyun Lee, Do Youn Oh, Sook Kyung Chang, Ji Hyun Park, Ji Yea Choi, Hyeon Ju Kim, Chan Young Ock, Tae Min Kim, Bhumsuk Keam, Yun Jeong Song, and Yoen Hee Ahn
- Subjects
Pharmacology ,medicine.medical_specialty ,business.industry ,Cmax ,medicine.disease ,Gastroenterology ,Thyroiditis ,Clinical trial ,Oncology ,Pharmacokinetics ,Pharmacodynamics ,Internal medicine ,Toxicity ,Cohort ,medicine ,Pharmacology (medical) ,business ,Adverse effect - Abstract
Introduction IMC-001 is a fully human IgG1 monoclonal antibody that binds to human PD-L1 (programmed death-ligand 1). This study evaluated the safety, pharmacokinetics, and pharmacodynamics of IMC-001 in patients with advanced solid tumors. Materials and Methods This open-labeled phase I study used a standard 3 + 3 dose-escalation design, with doses ranging from 2 to 20 mg/kg. IMC-001 was administered intravenously every 2 weeks until disease progression or unacceptable toxicity. The dose-limiting toxicity window was defined as 21 days from the first dose. Results Fifteen subjects were included in 5 dose-escalation cohorts. No dose-limiting toxicity was observed, and the maximum tolerated dose was not reached. The most common adverse events (AEs) were general weakness, decreased appetite, fever, and cough. No grade 4 or 5 treatment emergent AEs were reported during the study. One subject in the 2 mg/kg cohort showed grade 2 immune-induced thyroiditis and diabetes mellitus suspected to be related to IMC-001. Over the dose range of 2–20 mg/kg IMC-001, the AUC0–14d, AUC0—∞, and Cmax generally increased in a dose-proportional manner for each step of dose escalation. Of the 15 enrolled patients, 1 subject with rectal cancer showed a partial response, and the disease control rate was 33.3%. Conclusions IMC-001 demonstrated a favorable safety profile up to 20 mg/kg administered intravenously every 2 weeks and showed preliminary efficacy in patients with advanced solid tumors. Based on pharmacokinetic and pharmacodynamic data, 20 mg/kg was selected as the recommended phase II dose. Clinical trial identification NCT03644056 (date of registration: August 23, 2018).
- Published
- 2021
13. Preamble Design and Coarse Synchronization Using CAZAC Sequence for Uplink Cable Modem.
- Author
-
Youngje Kim, Junseo Lee, Hyunju Ha, Eungdon Lee, Yun-Jeong Song, Wangrok Oh, and Whanwoo Kim
- Published
- 2007
14. Implementation of the hybrid DMB platform based on the SMARTDMB.
- Author
-
Kwang-Yong Kim, Joungil Yun, Byungjun Bae, and Yun-Jeong Song
- Published
- 2013
- Full Text
- View/download PDF
15. Design and Performance Evaluation of Digital Radio Measurement Test Beds for Laboratory Test: DAB, DAB+, and T-DMB Audio.
- Author
-
Myung-Sun Baek, So Ra Park, Geon Kim, Yonghoon Lee, Hyoungsoo Lim, Yun-Jeong Song, Chae-Hun Im, and Yong-Tae Lee
- Published
- 2013
- Full Text
- View/download PDF
16. Laboratory Trials and Evaluations of In-Band Digital Radio Technologies: HD Radio and DRM+.
- Author
-
Myung-Sun Baek, So Ra Park, Geon Kim, Yonghoon Lee, Hyoungsoo Lim, Yun-Jeong Song, Chae-Hun Im, and Yong-Tae Lee
- Published
- 2013
- Full Text
- View/download PDF
17. A novel subspace tracking algorithm and its application to blind multiuser detection in cellular CDMA systems.
- Author
-
Imran Ali, Doug Nyun Kim, Yun-Jeong Song, and Naeem Zafar Azeemi
- Published
- 2010
- Full Text
- View/download PDF
18. Joint Carrier Recovery and Turbo Decoding Method for TDMA Burst MODEM Under Very Low SNRs.
- Author
-
Pansoo Kim, Kwonhue Choi, Yun-Jeong Song, Byoung-Hak Kim, Deock-Gil Oh, and Ho-Jin Lee
- Published
- 2006
- Full Text
- View/download PDF
19. Development of mobile broadband interactive satellite access system for Ku/Ka band.
- Author
-
Yun-Jeong Song, Pansoo Kim, Deock-Gil Oh, Soon-Ik Jeon, and Ho-Jin Lee
- Published
- 2006
- Full Text
- View/download PDF
20. Implementation and evaluation of hierarchical modulation based T-DMB transmission system.
- Author
-
Byungjun Bae, Hun-Hee Lee, Youngsu Kim, Yun-Jeong Song, and Hyoungsoo Lim
- Published
- 2014
- Full Text
- View/download PDF
21. Receptor Binding Affinities of Synthetic Cannabinoids Determined by Non-Isotopic Receptor Binding Assay
- Author
-
Da Eun Lee, Yun Jeong Song, Jaesuk Yun, Young-Hoon Kim, Jisoon Shin, Hye Jin Cha, Choon-Gon Jang, Soo Kyung Suh, and Kim Sungjin
- Subjects
Receptor binding assay ,Cannabinoid receptor ,Synthetic cannabinoids ,Health, Toxicology and Mutagenesis ,medicine.medical_treatment ,Non isotopic ,Human cannabinoid type I receptor (CB1) ,010501 environmental sciences ,Toxicology ,030226 pharmacology & pharmacy ,01 natural sciences ,03 medical and health sciences ,0302 clinical medicine ,Surface plasmon resonance ,Δ9-THC ,medicine ,Receptor ,0105 earth and related environmental sciences ,Binding affinities ,Chemistry ,Affinities ,Biochemistry ,Original Article ,Cannabinoid ,medicine.drug - Abstract
A major predictor of the efficacy of natural or synthetic cannabinoids is their binding affinity to the cannabinoid type I receptor (CB1) in the central nervous system, as the main psychological effects of cannabinoids are achieved via binding to this receptor. Conventionally, receptor binding assays have been performed using isotopes, which are inconvenient owing to the effects of radioactivity. In the present study, the binding affinities of five cannabinoids for purified CB1 were measured using a surface plasmon resonance (SPR) technique as a putative non-isotopic receptor binding assay. Results were compared with those of a radio-isotope-labeled receptor binding assay. The representative natural cannabinoid Δ9-tetrahydrocannabinol and four synthetic cannabinoids, JWH-015, JWH-210, RCS-4, and JWH-250, were assessed using both the SPR biosensor assay and the conventional isotopic receptor binding assay. The binding affinities of the test substances to CB1 were determined to be (from highest to lowest) 9.52 × 10−13 M (JWH-210), 6.54 × 10−12 M (JWH-250), 1.56 × 10−11 M (Δ9-tetrahydrocannabinol), 2.75 × 10−11 M (RCS-4), and 6.80 ×10−11 M (JWH-015) using the non-isotopic method. Using the conventional isotopic receptor binding assay, the same order of affinities was observed. In conclusion, our results support the use of kinetic analysis via SPR in place of the isotopic receptor binding assay. To replace the receptor binding affinity assay with SPR techniques in routine assays, further studies for method validation will be needed in the future.
- Published
- 2019
22. Hybrid delivery of 3DTV services via mobile broadcasting and wireless communication networks.
- Author
-
Woosuk Kim, Byungjun Bae, Yun-Jeong Song, and Hyoungsoo Lim
- Published
- 2013
- Full Text
- View/download PDF
23. Development of new data broadcasting service and verification platform using AT-DMB hierarchical feature.
- Author
-
Byungjun Bae, Joungil Yun, Kwang-Yong Kim, Soo In Lee, and Yun-Jeong Song
- Published
- 2012
- Full Text
- View/download PDF
24. A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors
- Author
-
Bhumsuk, Keam, Chan-Young, Ock, Tae Min, Kim, Do-Youn, Oh, Won Ki, Kang, Yeon Hee, Park, Jeeyun, Lee, Ji Hye, Lee, Yoen Hee, Ahn, Hyeon Ju, Kim, Sook Kyung, Chang, Jihyun, Park, Ji Yea, Choi, Yun Jeong, Song, and Young Suk, Park
- Subjects
Adult ,Male ,Dose-Response Relationship, Drug ,Maximum Tolerated Dose ,Antineoplastic Agents ,Middle Aged ,Antibodies, Monoclonal, Humanized ,B7-H1 Antigen ,Area Under Curve ,Neoplasms ,Humans ,Female ,Neoplasm Metastasis ,Aged - Abstract
Introduction IMC-001 is a fully human IgG1 monoclonal antibody that binds to human PD-L1 (programmed death-ligand 1). This study evaluated the safety, pharmacokinetics, and pharmacodynamics of IMC-001 in patients with advanced solid tumors. Materials and Methods This open-labeled phase I study used a standard 3 + 3 dose-escalation design, with doses ranging from 2 to 20 mg/kg. IMC-001 was administered intravenously every 2 weeks until disease progression or unacceptable toxicity. The dose-limiting toxicity window was defined as 21 days from the first dose. Results Fifteen subjects were included in 5 dose-escalation cohorts. No dose-limiting toxicity was observed, and the maximum tolerated dose was not reached. The most common adverse events (AEs) were general weakness, decreased appetite, fever, and cough. No grade 4 or 5 treatment emergent AEs were reported during the study. One subject in the 2 mg/kg cohort showed grade 2 immune-induced thyroiditis and diabetes mellitus suspected to be related to IMC-001. Over the dose range of 2-20 mg/kg IMC-001, the AUC
- Published
- 2021
25. 288 A phase 1 study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors
- Author
-
Jeeyun Lee, Do-Youn Oh, Yeon Hee Park, Tae Min Kim, Young Suk Park, Yun Jeong Song, Bhumsuk Keam, Chan Young Ock, Won Ki Kang, and Ji Hye Lee
- Subjects
medicine.medical_specialty ,business.industry ,Cmax ,Cancer ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,lcsh:RC254-282 ,Gastroenterology ,Discontinuation ,Pharmacokinetics ,Response Evaluation Criteria in Solid Tumors ,Internal medicine ,Pharmacodynamics ,Toxicity ,Medicine ,Adverse effect ,business - Abstract
Background IMC-001 is a fully human IgG1 monoclonal antibody that binds to human PD-L1 and mediate the antibody-dependent cell-mediated cytotoxicity. The main objectives of this study were to evaluate the safety, pharmacokinetics, and pharmacodynamics of IMC-001 in patients with advanced solid tumors. Here, we report final result of the phase 1 study of IMC-001. Methods This open-labeled phase 1 study used standard 3+3 dose-escalation design, dose ranging from 2 to 20 mg. IMC-001 was administered intravenously every two weeks until disease progression or unacceptable toxicity. Dose limiting toxicity (DLT) window was defined as 21 days from the first dose. Adverse events (AEs) were assessed using CTCAE v4.03, and tumor response was assessed by and the Response Evaluation Criteria In Solid Tumors (RECIST) version v1.1. Results Fifteen subjects (8 Male, 7 Female; Median age : 58 [range 39–69]) were included in 5 dose escalation cohorts. No DLT was observed and the maximum tolerated dose was not reached. Most common AEs were general weakness, decreased appetite, fever, and cough. No Grade 4 or 5 treatment emergent AEs (TEAEs) were reported during the study and no TEAE or serious AE led to treatment discontinuation or death. There were no infusion-related reactions during this study. Grade 2 immune-induced thyroiditis and diabetes mellitus suspected to be related to IMC-001 were seen in one subject at 2 mg/kg cohort. Over the dose range of 2 to 20 mg/kg IMC-001, AUC 0-14d, AUC 0—∞, and Cmax generally appeared to increase in a dose proportional manner for each step of dose escalation. Of the 15 enrolled patients, one subject with colon cancer showed partial response, and disease control rate was 33.3%. There were total 3 biliary tract cancer patients (1 GB cancer, 2 Cholangiocarcinoma) who received ≥3 lines of systemic therapies prior to this trial. They all had stable disease during IMC-001 treatment, and one cholangiocarcinoma subject received the treatment for 434 days. Conclusions IMC-001 demonstrated a favorable safety profile up to 20 mg/kg given IV every 2 weeks and showed encouraging preliminary efficacy in patients with advanced solid tumors. Based on PK and PD data, 20 mg/kg was selected as recommended Phase 2 dose (RP2D). Ethics Approval This study was approved by Institutional Review Board; approval number SMC 2018-01-007-001 and H-1801-042-913.
- Published
- 2020
26. Additional file 1 of Circulating TNF-like protein 1A (TL1A) is elevated early in rheumatoid arthritis and depends on TNF
- Author
-
Yun-Jeong Song, Choi, In Ah., Meylan, Françoise, M. Kristen Demoruelle, Farley, Taylor, Richard, Arianne C., Hawley, Eric, Botson, John, Hong, Yoo Jin, Lee, Eun Young, Mian, Sabina R., Bartlett C. Hamilton, Thiele, Geoffrey M., Mikuls, Ted R., Gara, Naveen, Ward, Chris D., Lamberth, Sarah, Deane, Kevin D., Heller, Theo, Ward, Michael M., Lee, David M., Thi-Sau Migone, Stohl, William, O’Dell, James R., Norris, Jill M., V. Michael Holers, Gregersen, Peter, Yeong-Wook Song, and Siegel, Richard M.
- Subjects
musculoskeletal diseases - Abstract
Additional file 1: Figure S1. Analysis of effect of methotrexate on TL1A levels from a second independent patient cohort. TL1A was measured in serum from an independent cohort of patients with RA treated with MTX for 4 months (66 good/moderate EULAR responders, 18 non-responders).
- Published
- 2020
- Full Text
- View/download PDF
27. Additional file 2 of Circulating TNF-like protein 1A (TL1A) is elevated early in rheumatoid arthritis and depends on TNF
- Author
-
Yun-Jeong Song, Choi, In Ah., Meylan, Françoise, M. Kristen Demoruelle, Farley, Taylor, Richard, Arianne C., Hawley, Eric, Botson, John, Hong, Yoo Jin, Lee, Eun Young, Mian, Sabina R., Bartlett C. Hamilton, Thiele, Geoffrey M., Mikuls, Ted R., Gara, Naveen, Ward, Chris D., Lamberth, Sarah, Deane, Kevin D., Heller, Theo, Ward, Michael M., Lee, David M., Thi-Sau Migone, Stohl, William, O’Dell, James R., Norris, Jill M., V. Michael Holers, Gregersen, Peter, Yeong-Wook Song, and Siegel, Richard M.
- Subjects
musculoskeletal diseases - Abstract
Additional file 2: Figure S2. Micro-CT Scoring system for erosions and joint damage (MCTS). A scoring system was devised for micro-CT measurements of hind paw joint scores incorporating a score for the ankle/tarsus, MTP, and distal joints with a total score of 0–30 points.
- Published
- 2020
- Full Text
- View/download PDF
28. Additional file 3 of Circulating TNF-like protein 1A (TL1A) is elevated early in rheumatoid arthritis and depends on TNF
- Author
-
Yun-Jeong Song, Choi, In Ah., Meylan, Françoise, M. Kristen Demoruelle, Farley, Taylor, Richard, Arianne C., Hawley, Eric, Botson, John, Hong, Yoo Jin, Lee, Eun Young, Mian, Sabina R., Bartlett C. Hamilton, Thiele, Geoffrey M., Mikuls, Ted R., Gara, Naveen, Ward, Chris D., Lamberth, Sarah, Deane, Kevin D., Heller, Theo, Ward, Michael M., Lee, David M., Thi-Sau Migone, Stohl, William, O’Dell, James R., Norris, Jill M., V. Michael Holers, Gregersen, Peter, Yeong-Wook Song, and Siegel, Richard M.
- Abstract
Additional file 3: Table S1. Demographic characteristics of SNUH cohort (data shown in Fig. 2 D-F and Fig. 3 B-D). Sr, serum; SF, synovial fluid; ESR, erythrocyte sedimentation rate; hsCRP, high sensitive C-reactive protein; RF, rheumatoid factor. Table S2. Demographic characteristics of patient subgroups from the SERA cohort.
- Published
- 2020
- Full Text
- View/download PDF
29. A synthetic cannabinoid JWH-210 reduces lymphoid organ weights and T-cell activator levels in mice via CB2 receptors
- Author
-
Hye Jin Cha, Young-Hoon Kim, Jisoon Shin, Sun Mi Gu, Hyung-Soo Kim, Jaesuk Yun, Tac-hyung Lee, Yun Jeong Song, Hye-Kyung Park, Hyun Jin Lee, and Kyoungmoon Han
- Subjects
0301 basic medicine ,Pharmacology ,medicine.medical_specialty ,Cannabinoid receptor ,Activator (genetics) ,medicine.medical_treatment ,T cell ,General Medicine ,Biology ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Endocrinology ,Cytokine ,medicine.anatomical_structure ,Rimonabant ,Internal medicine ,medicine ,Cannabinoid receptor type 2 ,Cannabinoid ,Receptor ,030217 neurology & neurosurgery ,medicine.drug - Abstract
The problem of new psychoactive substances (NPS) is emerging globally. However, the immunotoxicity of synthetic cannabinoids is not evaluated extensively yet. The purpose of the present study was to investigate whether synthetic cannabinoids (JWH-210 and JWH-030) induce adverse effects on lymphoid organs, viability of splenocytes and thymocytes, and immune cell activator and cytokines in mice. JWH-210 (10 mg/kg, 3 days, i.p.) is more likely to have cytotoxicity and reduce lymphoid organ weight than JWH-030 of ICR mice in vivo. We also demonstrated that JWH-210 administration resulted in the decrease of expression levels of T-cell activator including Cd3e, Cd3g, Cd74p31, and Cd74p41, while JWH-030 increased Cd3g levels. In addition, JWH-210 reduced expression levels of cytokines, such as interleukin-3, interleukin-5, and interleukin-6. Furthermore, we demonstrated that a CB2 receptor antagonist, AM630 inhibited JWH-210-induced cytotoxicity, whereas a CB1 receptor antagonist, rimonabant did not in primary cultured splenocytes. These results suggest that JWH-210 has a cytotoxicity via CB2 receptor action and results in decrement of lymphoid organ weights, T-cell activator, and cytokine mRNA expression levels.
- Published
- 2017
30. Circulating TNF-like protein 1A (TL1A) is elevated early in rheumatoid arthritis and depends on TNF
- Author
-
Taylor K. Farley, In Ah Choi, Geoffrey M. Thiele, Kevin D. Deane, Jill M. Norris, Eric T. Hawley, Sabina R. Mian, Eun Young Lee, Michael M. Ward, Naveen Gara, Peter K. Gregersen, V. Michael Holers, James R. O'Dell, Yun-Jeong Song, John Botson, Arianne C. Richard, Françoise Meylan, William Stohl, Ted R. Mikuls, Bartlett C. Hamilton, Christopher D. Ward, Theo Heller, David M. Lee, Thi-Sau Migone, S. Lamberth, Richard M. Siegel, Yoo Jin Hong, Yeong Wook Song, and M. Kristen Demoruelle
- Subjects
Tumor Necrosis Factor Ligand Superfamily Member 15 ,medicine.medical_specialty ,lcsh:Diseases of the musculoskeletal system ,medicine.medical_treatment ,Arthritis ,Arthritis, Rheumatoid ,03 medical and health sciences ,Mice ,0302 clinical medicine ,Internal medicine ,Synovial Fluid ,medicine ,Synovial fluid ,Animals ,Humans ,Rheumatoid arthritis ,030203 arthritis & rheumatology ,Autoimmune disease ,TNFSF15 ,business.industry ,Tumor Necrosis Factor-alpha ,medicine.disease ,Arthritis, Experimental ,Rheumatology ,Cytokine ,Methotrexate ,Immunology ,Tumor necrosis factor-like cytokine 1A ,Biomarker (medicine) ,Cytokines ,Collagen-induced arthritis ,Tumor necrosis factor alpha ,Tumor Necrosis Factor Inhibitors ,lcsh:RC925-935 ,business ,030215 immunology ,Research Article - Abstract
Background The tumor necrosis factor (TNF) superfamily cytokine TNF-like protein 1A (TL1A) and its receptor DR3 are essential for diverse animal models of autoimmune disease and may be pathogenic in rheumatoid arthritis (RA). However, the relationship of TL1A to disease duration, activity, and response to anti-TNF and other therapies in RA is not clear. Methods We measured soluble TL1A in synovial fluid (SF), serum, or plasma from RA first-degree relatives (FDRs) and in early RA and established disease. We measured the effects of anti-TNF and methotrexate (MTX) therapy on circulating TL1A from multiple independent RA treatment trials. We also determined the ability of a blocking anti-TL1A antibody to inhibit clinical disease and articular bone destruction in the murine collagen-induced arthritis (CIA) model of human RA. Results Soluble TL1A was specifically elevated in the blood and SF of patients with RA compared to patients with other diseases and was elevated early in disease and in at-risk anti-cyclic citrullinated peptide (CCP) (+) first-degree relatives (FDRs). Therapeutic TNF inhibition reduced serum TL1A in both responders and non-responders, whereas TL1A declined following MTX treatment only in responders. In murine CIA, TL1A blockade was clinically efficacious and reduced bone erosions. Conclusions TL1A is specifically elevated in RA from early in the disease course and in at-risk FDRs. The decline in TL1A after TNF blockade suggests that TL1A levels may be a useful biomarker for TNF activity in RA. These results support the further investigation of the relationship between TL1A and TNF and TL1A blockade as a potential therapeutic strategy in RA.
- Published
- 2019
31. Rapid expansion and auto-grafting efficiency of porcine full skin expanded by a skin bioreactor ex vivo
- Author
-
Sun Hee An, Jeung-Soo Huh, Man-Il Huh, Yun-Jeong Song, Sang-Hyun An, Jeong Ok Lim, Hwi-Gang Kim, Eun-Chang Choi, and Woo Sung Choi
- Subjects
0301 basic medicine ,Materials science ,integumentary system ,Rapid expansion ,Biomedical Engineering ,Medicine (miscellaneous) ,Scars ,Grafting ,Artificial skin ,030207 dermatology & venereal diseases ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,In vivo ,Operating time ,medicine ,Bioreactor ,Original Article ,medicine.symptom ,Ex vivo ,Biomedical engineering - Abstract
Full skin auto-grafts are required for reconstruction of skin burns and trauma scars. However, currently available clinical approaches such as sheet skin graft, mesh skin grafts, artificial skin graft, and in vivo skin expansion have limitations due to their potential danger for secondary damage and scar formation at the donor site, and discomfort during skin expansion. We developed an advanced bioreactor system and evaluated its function in skin expansion using porcine full skin. The reactor was designed as a pneumatic cylinder type, was programmed to adjust the pressure and the operating time. The system was composed of culture chamber unit, environmental control unit, and monitoring unit. Skins were expanded at 200 kPa pneumatic force and the expanded skins were analyzed by immunohistochemistry and histology. Furthermore we carried out auto-grafting experiment of the expanded skins in vivo using Yucatan pigs and skins were harvested and histologically analyzed after 8 weeks. The results showed that the bioreactor expanded skins to 160% in 4 hours. Histological analysis of the expanded skins revealed that epidermal cells and dermal fibroblasts were viable and remained integrity. The results of auto-grafting experiment indicated that fibrosis and scars were not detected in the grafted skins. This study demonstrates that the newly developed skin bioreactor enabled to obtain large sized full skin rapidly and successful grating.
- Published
- 2016
32. Synthetic cannabinoid, JWH-030, induces QT prolongation through hERG channel inhibition
- Author
-
Hye Jin Cha, Kyoung Moon Han, Jisoon Shin, Sun Mi Gu, Kyung Sik Yoon, Hyun Jin Lee, Hye-Kyung Park, Jaesuk Yun, Young-Hoon Kim, Hyung-Soo Kim, Tac-hyung Lee, Hyewon Seo, and Yun Jeong Song
- Subjects
0301 basic medicine ,Cannabinoid receptor ,biology ,Chemistry ,Health, Toxicology and Mutagenesis ,medicine.medical_treatment ,hERG ,Antagonist ,Pharmacology ,Toxicology ,QT interval ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Rimonabant ,Synthetic cannabinoids ,medicine ,biology.protein ,Cannabinoid receptor type 2 ,Cannabinoid ,030217 neurology & neurosurgery ,medicine.drug - Abstract
The problem of new psychoactive substance (NPS) abuse, which includes synthetic cannabinoids, is emerging globally, and the cardiotoxicity of these synthetic cannabinoids has not yet been evaluated extensively. In the present study, we investigated the effects of synthetic cannabinoids on the cytotoxicity, human Ether-a-go-go-related gene (hERG) channel, action potential duration (APD), and QT interval. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay showed that JWH-030 was more cytotoxic than JWH-210, JWH-250, and RCS4 in H9c2 cells at 0.1 μM. In addition, the cytotoxicity was associated with its pro-apoptotic effects as evidenced by the increase in caspase-3 levels. We demonstrated that a cannabinoid receptor type 2 (CB2) antagonist, AM630, inhibited JWH-030-induced cytotoxicity, whereas a CB1 antagonist, rimonabant, did not. Furthermore, fluorescence polarization assay showed JWH-030 to block the hERG channel (half-maximal inhibitory concentration, IC50 was 88.36 μM). JWH-030 significantly reduced the APD at 90% repolarization (APD90) in rabbit Purkinje fibers and decreased the left ventricular end diastolic pressure (LVEDP) in Langendorff-perfused Sprague-Dawley (SD) rat hearts at 30 μM. In addition, the electrocardiogram (ECG) measurement revealed that the intravenous injection of JWH-030 (0.5 mg kg−1) prolonged the QT interval in SD rats. These results suggest that JWH-030 is cytotoxic and its cytotoxicity is mediated by its action on the CB2 receptor; it prolongs the QT interval by regulating ion current channels and APD.
- Published
- 2016
33. Cardiovascular Safety Pharmacology of Sibutramine
- Author
-
Eunyong Chung, Hyung-Soo Kim, Jaesuk Yun, Yun Jeong Song, Dae Hyun Cho, Ji Soon Shin, Hey Jin Cha, Won-Keun Seong, Ki Hwan Choi, Kyoung Moon Han, and Young-Hoon Kim
- Subjects
Drug ,media_common.quotation_subject ,hERG ,QT prolongation ,Pharmacology ,Biochemistry ,QT interval ,Drug Discovery ,Heart rate ,medicine ,Sibutramine ,Adverse effect ,media_common ,biology ,business.industry ,Blood pressure ,Beagle dogs ,biology.protein ,Anorectic ,Molecular Medicine ,Original Article ,business ,medicine.drug - Abstract
Sibutramine is an anorectic that has been banned since 2010 due to cardiovascular safety issues. However, counterfeit drugs or slimming products that include sibutramine are still available in the market. It has been reported that illegal sibutramine-contained pharmaceutical products induce cardiovascular crisis. However, the mechanism underlying sibutramine-induced cardiovascular adverse effect has not been fully evaluated yet. In this study, we performed cardiovascular safety pharmacology studies of sibutramine systemically using by hERG channel inhibition, action potential duration, and telemetry assays. Sibutramine inhibited hERG channel current of HEK293 cells with an IC50 of 3.92 μM in patch clamp assay and increased the heart rate and blood pressure (76 Δbpm in heart rate and 51 ΔmmHg in blood pressure) in beagle dogs at a dose of 30 mg/kg (per oral), while it shortened action potential duration (at 10 μM and 30 μM, resulted in 15% and 29% decreases in APD50, and 9% and 17% decreases in APD90, respectively) in the Purkinje fibers of rabbits and had no effects on the QTc interval in beagle dogs. These results suggest that sibutramine has a considerable adverse effect on the cardiovascular system and may contribute to accurate drug safety regulation.
- Published
- 2015
34. A synthetic cannabinoid JWH-210 reduces lymphoid organ weights and T-cell activator levels in mice via CB
- Author
-
Sun Mi, Gu, Hyun Jin, Lee, Tac-Hyung, Lee, Yun Jeong, Song, Young-Hoon, Kim, Kyoung-Moon, Han, Jisoon, Shin, Hye-Kyung, Park, Hyung Soo, Kim, Hye Jin, Cha, and Jaesuk, Yun
- Subjects
Male ,Mice, Inbred ICR ,Indoles ,Thymocytes ,Cell Survival ,Lymphoid Tissue ,T-Lymphocytes ,Organ Size ,Naphthalenes ,Tumor Necrosis Factor Receptor Superfamily, Member 7 ,Receptor, Cannabinoid, CB2 ,Mice ,Piperidines ,B7-1 Antigen ,Animals ,Cytokines ,Pyrazoles ,Female ,Rimonabant ,Spleen - Abstract
The problem of new psychoactive substances (NPS) is emerging globally. However, the immunotoxicity of synthetic cannabinoids is not evaluated extensively yet. The purpose of the present study was to investigate whether synthetic cannabinoids (JWH-210 and JWH-030) induce adverse effects on lymphoid organs, viability of splenocytes and thymocytes, and immune cell activator and cytokines in mice. JWH-210 (10 mg/kg, 3 days, i.p.) is more likely to have cytotoxicity and reduce lymphoid organ weight than JWH-030 of ICR mice in vivo. We also demonstrated that JWH-210 administration resulted in the decrease of expression levels of T-cell activator including Cd3e, Cd3g, Cd74p31, and Cd74p41, while JWH-030 increased Cd3g levels. In addition, JWH-210 reduced expression levels of cytokines, such as interleukin-3, interleukin-5, and interleukin-6. Furthermore, we demonstrated that a CB
- Published
- 2017
35. Implementation and Field Test for Smart Hybrid Mobile Broadcasting System
- Author
-
Hyoungsoo Lim, Yun-Jeong Song, Young-Su Kim, and Jeongil Yun
- Subjects
Service (business) ,Computer science ,business.industry ,Wireless network ,Digital multimedia broadcasting ,Broadcasting (networking) ,Default gateway ,Hybrid system ,Signal Processing ,Wireless ,Data as a service ,Electrical and Electronic Engineering ,Telecommunications ,business ,Computer network - Abstract
The era of convergence is being applied to all areas of Information and Communication Technology (ICT). The convergence of broadcasting service and communication service almost occurs on smart devices including smartphone. The smart hybrid Digital Multimedia Broadcasting (DMB) is a typical example of the convergence of broadcasting and wireless communication service. The hybrid mobile broadcasting service can support seamless video, 3D, high quality, and additional data services based on network connection between the broadcasting and wireless network. The gateway and terminal (including apps on the smartphone) take the role of the main components on the hybrid service. This paper presents the service concept, main components structure, the implementation of gateway and terminals, and field test to the urban areas for the mobile hybrid system.
- Published
- 2014
36. Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy
- Author
-
Saet Byoul Lee, Kyung Ah Kim, Yun-Jeong Song, Yunju Jeong, Yoo Hyeon-Seok, Yan Zhou, Paul H. Song, Jaehyun Choi, Eunjin Lee, Ji Min Lee, Dae-Soon Son, Tae-jin Ahn, Young Mi Oh, Joseph C. Murray, Bogyou Kim, Shangzi Wang, Louis M. Weiner, and Park Hye Hyang
- Subjects
Cancer Research ,Small interfering RNA ,Pyridines ,medicine.medical_treatment ,Biology ,Antibodies, Monoclonal, Humanized ,Article ,Receptor tyrosine kinase ,Targeted therapy ,Crizotinib ,Peptide Library ,Cell Line, Tumor ,Neoplasms ,Genetics ,medicine ,Humans ,Molecular Targeted Therapy ,RNA, Small Interfering ,Protein Kinase Inhibitors ,Molecular Biology ,Gene knockdown ,Integrin beta3 ,Antibodies, Monoclonal ,Cancer ,Proto-Oncogene Proteins c-met ,medicine.disease ,Receptors, Fibroblast Growth Factor ,Molecular biology ,Gene Expression Regulation, Neoplastic ,Drug Resistance, Neoplasm ,Fibroblast growth factor receptor ,Cancer cell ,biology.protein ,Cancer research ,Pyrazoles ,Signal transduction ,Signal Transduction - Abstract
Met is a receptor tyrosine kinase that promotes cancer progression. In addition, Met has been implicated in resistance of tumors to various targeted therapies such as epidermal growth factor receptor inhibitors in lung cancers, and has been prioritized as a key molecular target for cancer therapy. However, the underlying mechanism of resistance to Met-targeting drugs is poorly understood. Here, we describe screening of 1310 genes to search for key regulators related to drug resistance to an anti-Met therapeutic antibody (SAIT301) by using a small interfering RNA-based synthetic lethal screening method. We found that knockdown of 69 genes in Met-amplified MKN45 cells sensitized the antitumor activity of SAIT301. Pathway analysis of these 69 genes implicated fibroblast growth factor receptor (FGFR) as a key regulator for antiproliferative effects of Met-targeting drugs. Inhibition of FGFR3 increased target cell apoptosis through the suppression of Bcl-xL expression, followed by reduced cancer cell growth in the presence of Met-targeting drugs. Treatment of cells with the FGFR inhibitors substantially restored the efficacy of SAIT301 in SAIT301-resistant cells and enhanced the efficacy in SAIT301-sensitive cells. In addition to FGFR3, integrin β3 is another potential target for combination treatment with SAIT301. Suppression of integrin β3 decreased AKT phosphorylation in SAIT301-resistant cells and restored SAIT301 responsiveness in HCC1954 cells, which are resistant to SAIT301. Gene expression analysis using CCLE database shows that cancer cells with high levels of FGFR and integrin β3 are resistant to crizotinib treatment, suggesting that FGFR and integrin β3 could be used as predictive markers for Met-targeted therapy and provide a potential therapeutic option to overcome acquired and innate resistance for the Met-targeting drugs.
- Published
- 2014
37. Scalable BWS Service for Hybrid DMB Data Broadcasting
- Author
-
Byungjun Bae, Hyongsoo Lim, Yun-Jeong Song, and Joungil Yun
- Subjects
Service (business) ,Transmission (telecommunications) ,Computer science ,business.industry ,Web traffic ,Scalability ,Mobile Web ,Mobile telephony ,Broadcasting ,business ,Digital multimedia broadcasting ,Computer network - Abstract
The BWS (broadcast website) data broadcasting service for terrestrial DMB (digital multimedia broadcasting) has a great advantage that it can provide a website like service through broadcast without web traffic to a plurality of receiving terminals. However, the value of BWS has not been recognized due to the development of mobile communication technology and changes in the environment, where mobile web services through smart devices such as smart phones and pads are common. Recently, various hybrid service technologies provided through hybrid broadcasting, a fusion of broadcasting and communications, have been developed. In this paper, we propose a scalable BWS dividing the hierarchy of BWS into transmission layers and present its application for hybrid DMB data broadcasting services.
- Published
- 2013
38. Laboratory Trials and Evaluations of In-Band Digital Radio Technologies: HD Radio and DRM+
- Author
-
Yun-Jeong Song, Yong-Tae Lee, Myung-Sun Baek, Chae-Hun Im, Yong-Hoon Lee, Hyoungsoo Lim, Geon Kim, and Sunji Park
- Subjects
Broadcast engineering ,business.industry ,Computer science ,ComputerSystemsOrganization_COMPUTER-COMMUNICATIONNETWORKS ,Digital radio ,Broadcasting ,Digital audio broadcasting ,Hardware_GENERAL ,Winlink ,Media Technology ,HD Radio ,Digital broadcasting ,Electrical and Electronic Engineering ,Telecommunications ,business ,Frequency modulation - Abstract
Many countries are converting their analog communication and broadcasting services into digital services. However, digital radio broadcasting service is still an issue to be addressed. In order to provide digital radio broadcasting service, it is very important to choose the most appropriate digital radio method for their frequency environment and listeners. This paper depicts laboratory test results of in-band digital radio technologies, HD Radio and DRM+. To contribute to decision of digital radio standard and design of digital radio transmission network, various results of many test items are expressed.
- Published
- 2013
39. Design and Performance Evaluation of Digital Radio Measurement Test Beds for Laboratory Test: DAB, DAB+, and T-DMB Audio
- Author
-
Yong-Tae Lee, Yong-Hoon Lee, Geon Kim, Yun-Jeong Song, Sora Park, Hyoungsoo Lim, Myung-Sun Baek, and Chae-Hun Im
- Subjects
Broadcast engineering ,business.industry ,Computer science ,Digital radio ,Band III ,Broadcasting ,Digital multimedia broadcasting ,Digital audio broadcasting ,Electronic engineering ,Digital broadcasting ,Digital television ,Electrical and Electronic Engineering ,business ,Instrumentation ,Radio broadcasting ,Computer hardware ,Digital audio - Abstract
This paper depicts the digital radio test bed design and performance evaluation for digital audio broadcasting, DAB+, and terrestrial digital multimedia broadcasting audio systems that are representative digital radio broadcasting standards operating in band III (out-of-band). We consider a laboratory trial to measure the performance of each digital radio system. The existing broadcasting measurement systems have some limitations, such as the small number of available measurement items and broadcasting systems. However, the introduced test bed can cover above representative three digital radio systems and measure various performance parameters. This paper minutely describes not only the test bed designs but also various test results according to the measurement items. Therefore, this paper can help select an appropriate digital radio standard.
- Published
- 2013
40. A new anti-c-met antibody selected by a mechanism-based dual-screening method: Therapeutic potential in cancer
- Author
-
Bogyou Kim, Do-Hyun Nam, Kwang Ho Cheong, Ji Min Lee, Saet Byoul Lee, Jaehyun Choi, Kyung Eun Kim, Mi-Young Cho, Geun Woong Kim, Yun-Jeong Song, Paul H. Song, Young Mi Oh, Kyung Ah Kim, and Yunju Jeong
- Subjects
C-Met ,Angiogenesis ,media_common.quotation_subject ,chemistry.chemical_compound ,Isoantibodies ,Cell Line, Tumor ,Neoplasms ,medicine ,Humans ,Internalization ,Molecular Biology ,Protein kinase B ,Cell Proliferation ,media_common ,Neovascularization, Pathologic ,biology ,Hepatocyte Growth Factor ,Antibodies, Monoclonal ,Cancer ,Articles ,Cell Biology ,General Medicine ,Proto-Oncogene Proteins c-met ,medicine.disease ,Xenograft Model Antitumor Assays ,Molecular biology ,chemistry ,Cancer research ,biology.protein ,Hepatocyte growth factor ,Antibody ,Tyrosine kinase ,medicine.drug - Abstract
c-Met, the high affinity receptor for hepatocyte growth factor (HGF), is one of the most frequently activated tyrosine kinases in many human cancers and a target for cancer therapy. However, inhibitory targeting of c-Met with antibodies has proven difficult, because most antibodies have intrinsic agonist activity. Therefore, the strategy for reducing the agonism is critical for successful development of cancer therapies based on anti-c-Met antibodies. Here we developed a mechanism-based assay method for rapid screening of anti-c-Met antibodies, involving the determination of Akt phosphorylation and c-Met degradation for agonism and efficacy, respectively. Using the method, we identified an antibody, F46, that binds to human c-Met with high affinity (Kd = 2.56 nM) and specificity, and induces the degradation of c-Met in multiple cancer cells (including MKN45, a gastric cancer cell line) with minimal activation of c-Met signaling. F46 induced c-Met internalization in both HGF-dependent and HGF-independent cells, suggesting that the degradation of c-Met results from antibody-mediated receptor internalization. Further-more, F46 competed with HGF for binding to c-Met, resulting in the inhibition of both HGF-mediated invasion and angiogenesis. Consistently, F46 inhibited the proliferation of MKN45 cells, in which c-Met is constitutively activated in an HGF-independent manner. Xenograft analysis revealed that F46 markedly inhibits the growth of subcutaneously implanted gastric and lung tumors. These results indicate that F46, identified by a novel mechanism-based assay, induces c-Met degradation with minimal agonism, implicating a potential role of F46 in therapy of human cancers.
- Published
- 2012
41. Synthetic Cannabinoid-Induced Immunosuppression Augments Cerebellar Dysfunction in Tetanus-Toxin Treated Mice
- Author
-
Yun Jeong Song, Seonhwa Seong, Sun Mi Gu, Hye Jin Cha, Jisoon Shin, Young-Hoon Kim, Kyoung Moon Han, Kikyung Jung, Tac-hyung Lee, Hyung-Soo Kim, Hokyung Oh, Chiyoung Ahn, Hye-Kyung Park, and Jaesuk Yun
- Subjects
0301 basic medicine ,Cerebellum ,T cell ,medicine.medical_treatment ,Pharmacology ,Biology ,medicine.disease_cause ,T cell activator ,Biochemistry ,03 medical and health sciences ,Immune system ,Motor impairment ,Drug Discovery ,Synthetic cannabinoids ,medicine ,Cytokine ,Tetanus ,Toxin ,Glutamate receptor ,medicine.disease ,Tetanus toxin ,030104 developmental biology ,medicine.anatomical_structure ,New psychoactive substances ,Immunology ,Molecular Medicine ,Original Article ,Cannabinoid ,Glutamate ,medicine.drug - Abstract
Synthetic cannabinoids are one of most abused new psychoactive substances. The recreational use of abused drug has aroused serious concerns about the consequences of these drugs on infection. However, the effects of synthetic cannabinoid on resistance to tetanus toxin are not fully understood yet. In the present study, we aimed to determine if the administration of synthetic cannabinoids increase the susceptibility to tetanus toxin-induced motor behavioral deficit and functional changes in cerebellar neurons in mice. Furthermore, we measured T lymphocytes marker levels, such as CD8 and CD4 which against tetanus toxin. JWH-210 administration decreased expression levels of T cell activators including cluster of differentiation (CD) 3e, CD3γ, CD74p31, and CD74p41. In addition, we demonstrated that JWH-210 induced motor impairment and decrement of vesicle-associated membrane proteins 2 levels in the cerebellum of mice treated with tetanus toxin. Furthermore, cerebellar glutamatergic neuronal homeostasis was hampered by JWH-210 administration, as evidenced by increased glutamate concentration levels in the cerebellum. These results suggest that JWH-210 may increase the vulnerability to tetanus toxin via the regulation of immune function.
- Published
- 2016
42. An Efficient and Flexible Hybrid Conditional Access System for Advanced T-DMB
- Author
-
Yun-Jeong Song, Hyung-Yoon Seo, Soo-In Lee, Jong-Deok Kim, and Byungjun Bae
- Subjects
Engineering ,General Computer Science ,business.industry ,Conditional access ,Telecommunications network ,Electronic, Optical and Magnetic Materials ,Digital multimedia broadcasting ,Computer architecture ,Transmission (telecommunications) ,Embedded system ,Channel (programming) ,ComputingMethodologies_SYMBOLICANDALGEBRAICMANIPULATION ,Hardware_CONTROLSTRUCTURESANDMICROPROGRAMMING ,Electrical and Electronic Engineering ,business - Abstract
This letter presents a hybrid conditional access system (CAS) for advanced terrestrial digital multimedia broadcasting (ATDMB). The proposed architecture is characterized by its use of a unified CAS channel and various communication networks for CAS message transmissions. We implement a prototype CAS based on the hybrid architecture, which improves the CAS message transmission efficiency greatly compared to the existing T-DMB CAS standard and supports various AT-DMB interlayer services more easily and efficiently.
- Published
- 2011
43. Highly Ordered Poly(3-hexylthiophene) Rod Polymers via Block Copolymer Self-Assembly
- Author
-
Won Ho Jo, Jea Uk Lee, Su Yeon Choi, Jin Wook Lee, Yun Jeong Song, Seung Hyun Kim, and Sle Lee
- Subjects
Inorganic Chemistry ,chemistry.chemical_classification ,Materials science ,Polymers and Plastics ,chemistry ,Chemical engineering ,Organic Chemistry ,Materials Chemistry ,Copolymer ,Self-assembly ,Polymer - Published
- 2011
44. The TNF-family cytokine TL1A drives IL-13-dependent small intestinal inflammation
- Author
-
Ian-James Malm, Margaret M. Mentink-Kane, Yun-Jeong Song, Françoise Meylan, Thi-Sau Migone, Sarah Villarreal, Erin Kahle, Haydee L. Ramos, Thomas A. Wynn, Larry Lo, Richard M. Siegel, Ivan J. Fuss, Krishika Acharya, and Warren Strober
- Subjects
medicine.medical_treatment ,Immunology ,T-cell receptor ,Gastroenterology ,FOXP3 ,Biology ,medicine.disease ,Inflammatory bowel disease ,Cytokine ,Interleukin 13 ,medicine ,Immunology and Allergy ,Tumor necrosis factor alpha ,Colitis ,Receptor ,Death receptor 3 - Abstract
The tumor necrosis factor (TNF)-family cytokine TL1A (TNFSF15) costimulates T cells through its receptor DR3 (TNFRSF25) and is required for autoimmune pathology driven by diverse T-cell subsets. TL1A has been linked to human inflammatory bowel disease (IBD), but its pathogenic role is not known. We generated transgenic mice that constitutively express TL1A in T cells or dendritic cells. These mice spontaneously develop IL-13-dependent inflammatory small bowel pathology that strikingly resembles the intestinal response to nematode infections. These changes were dependent on the presence of a polyclonal T-cell receptor (TCR) repertoire, suggesting that they are driven by components in the intestinal flora. Forkhead box P3 (FoxP3)-positive regulatory T cells (Tregs) were present in increased numbers despite the fact that TL1A suppresses the generation of inducible Tregs. Finally, blocking TL1A-DR3 interactions abrogates 2,4,6 trinitrobenzenesulfonic acid (TNBS) colitis, indicating that these interactions influence other causes of intestinal inflammation as well. These results establish a novel link between TL1A and interleukin 13 (IL-13) responses that results in small intestinal inflammation, and also establish that TL1A-DR3 interactions are necessary and sufficient for T cell-dependent IBD.
- Published
- 2011
45. A novel subspace tracking algorithm and its application to blind multiuser detection in cellular CDMA systems
- Author
-
N.Z. Azeemi, Doug Nyun Kim, Imran Ali, and Yun-Jeong Song
- Subjects
Computational complexity theory ,Computer Networks and Communications ,Computer science ,Code division multiple access ,MathematicsofComputing_NUMERICALANALYSIS ,Approximation algorithm ,Detection theory ,Performance improvement ,Multiuser detection ,Algorithm ,Subspace topology ,Eigenvalues and eigenvectors ,Information Systems - Abstract
In this paper, we propose and develop a new algorithm for the principle subspace tracking by orthonormalizing the eigenvectors using an approximation of Gram-Schmidt procedure. We carry out a novel mathematical derivation to show that when this approximated version of Gram-Schmidt procedure is added to a modified form of projection approximation subspace tracking deflation (PASTd) algorithm, the eigenvectors can be orthonormalized within a linear computational complexity. While the PASTd algorithm tries to extracts orthonormalized eigenvectors, the new scheme orthonormalizes the eigenvectors after their extraction, yielding much more tacking efficiency. We apply the new tracking scheme for blind adaptive multiuser detection for non-stationary cellular CDMA environment and use extensive simulation results to demonstrate the performance improvement of the proposed scheme.
- Published
- 2010
46. New insights into T cell biology and T cell-directed therapy for autoimmunity, inflammation, and immunosuppression
- Author
-
John J. O'Shea, Richard M. Siegel, Scott M. Steward-Tharp, and Yun-Jeong Song
- Subjects
medicine.medical_specialty ,Lineage commitment ,General Neuroscience ,medicine.medical_treatment ,T cell ,Immunosuppression ,Context (language use) ,Inflammation ,Biology ,medicine.disease_cause ,General Biochemistry, Genetics and Molecular Biology ,Organ transplantation ,Autoimmunity ,medicine.anatomical_structure ,History and Philosophy of Science ,Immunology ,medicine ,T-helper cell differentiation ,medicine.symptom - Abstract
T cell-directed therapies have become mainstays in the management of various autoimmune diseases and organ transplantation. The understanding of T cell biology has expanded greatly since the development of most agents currently in use. Here we discuss important recent discoveries pertaining to T helper cell differentiation, lineage commitment, and function. Within this context, we examine existing T cell-directed therapies, including new agents being evaluated in clinical and preclinical studies. We also use recent findings to speculate on novel targets.
- Published
- 2010
47. A Dual Regulatory Role of Apurinic/Apyrimidinic Endonuclease 1/Redox Factor-1 in HMGB1-Induced Inflammatory Responses
- Author
-
Eun-Kyeong Jo, Chul-Su Yang, Kwang–Kyu Kim, Hye-Mi Lee, Dong-Min Shin, Chung-Hyun Cho, Yun Jeong Song, Jae-Min Yuk, Byeong Hwa Jeon, and Sang Ki Lee
- Subjects
Small interfering RNA ,Physiology ,p38 mitogen-activated protein kinases ,Clinical Biochemistry ,Enzyme-Linked Immunosorbent Assay ,chemical and pharmacologic phenomena ,HMGB1 ,Biochemistry ,DNA-(Apurinic or Apyrimidinic Site) Lyase ,Extracellular ,Humans ,Gene silencing ,HMGB1 Protein ,Molecular Biology ,DNA Primers ,General Environmental Science ,Inflammation ,Base Sequence ,biology ,Reverse Transcriptase Polymerase Chain Reaction ,Kinase ,Cell Biology ,Transfection ,Molecular biology ,Cell biology ,biology.protein ,General Earth and Planetary Sciences ,Cytokine secretion - Abstract
Apurinic/apyrimidinic endonuclease 1/Redox factor-1 (APE1) is a multifunctional protein involved in reduction-oxidation regulation. High-mobility group box 1 (HMGB1) is released by necrotic cells and various inflammatory stimuli, acting as an inflammatory marker in sepsis and autoimmune diseases. Here, we report the dual regulatory role of APE1 in inflammatory signaling to extracellular HMGB1 or in the release of endogenous HMGB1 in human monocytes/macrophages. Forced cytoplasmic overexpression of APE1 profoundly attenuated the upregulation of HMGB1-mediated reactive oxygen species generation, cytokine secretion, and cyclooxygenase-2 expression by primary monocytes and macrophage-like THP-1 cell lines. In addition, HMGB1-induced activation of p38 and c-Jun N-terminal kinase (JNK), but not extracellular signal-regulated kinase 1/2, was strongly abrogated by the overexpression of APE1. The activation of apoptosis signal-regulating kinase 1 was required for both the p38 and JNK activation challenge with HMGB1. The extracellular release of HMGB1 by activated macrophages was inhibited by APE1 transfection. Small interfering RNA (siRNA) knockdown of endogenous APE1 impaired HMGB1-mediated cytokine expression and MAPK activation in THP-1 cells. HMGB1 stimulation induced the translocation of APE1 to the nucleus of the cell. In addition, APE1 silencing via siRNA transfection inhibited both the nuclear and cytoplasmic expression of APE1. These data identify APE1 as a novel dual regulator of inflammatory signaling to HMGB1 by human monocytes/macrophages. The modulation of cytosolic APE1 expression might be useful as a potential therapeutic modality for the treatment of inflammatory or autoimmune diseases.
- Published
- 2009
48. Korean Red Ginseng Extract inhibits Tumor Necrosis Factor-alpha-induced Monocyte Adhesion in the Human Endothelial Cells
- Author
-
Jae-Hwan Lee, Sang Ki Lee, Chung-Hyun Cho, Yun Jeong Song, Jin Bong Park, Kwon Ho Lee, Hyo Shin Kim, Eun Jung Cho, Se Hoon Kim, Byeong Hwa Jeon, Hee Kyoung Joo, In Whan Seong, and Gun Kang
- Subjects
Cell adhesion molecule ,Adhesion ,Biology ,medicine.disease ,Biochemistry, Genetics and Molecular Biology (miscellaneous) ,Calcium in biology ,Umbilical vein ,Cell biology ,Complementary and alternative medicine ,medicine ,Tumor necrosis factor alpha ,Endothelial dysfunction ,Cell adhesion ,Intracellular ,Biotechnology - Abstract
Vascular inflammation is an important step in the development of cardiovascular disorder. Since it has not been known whether Korean red ginseng has a role to play on the vascular inflammation, we investigated the effects of Korean red ginseng extract (KRGE) on monocyte adhesion and its underlying signaling mechanism. Monocyte adhesion assay and Western blot were conducted on the human umbilical vein endothelial cells to study monocyte adhesion and the expression of adhesion molecules. Intracellular calcium was measured with Fura-2 fluorescent staining, and superoxide production was measured with lucigenin chemiluminescence in the endothelial cells. KRGE inhibits tumor necrosis factor (TNF)-alpha-induced monocyte adhesion on the endothelial cells at the range of 0.03~1 ㎎/㎖. TNF-alpha-induced vascular cell adhesion molecule-1 and intercellular cell adhesion molecule-1 expression were inhibited by the pretreatment of KRGE in the endothelial cells. KRGE also inhibits TNF-alpha-induced intracellular calcium and the superoxide production in the endothelial cells. This study first demonstrated that KRGE inhibits TNF-alpha-induced monocyte adhesion by inhibiting the adhesion molecule expression, intracellular calcium and superoxide production in the endothelial cells. Therefore, the anti-inflammatory function of KRGE may be contributed to protecting the endothelial dysfunction in the vascular inflammatory disorders.
- Published
- 2008
49. Alteration of APE1/ref-1 expression in non-small cell lung cancer: The implications of impaired extracellular superoxide dismutase and catalase antioxidant systems
- Author
-
Jae Hyeon Yu, Jin-Man Kim, Dae Goon Yoo, Eun Jung Cho, Yun Jeong Song, Byeong Hwa Jeon, Jin Bong Park, Seung Pyung Lim, and Sang Ki Lee
- Subjects
Pulmonary and Respiratory Medicine ,Cancer Research ,Pathology ,medicine.medical_specialty ,Lung Neoplasms ,Blotting, Western ,medicine.disease_cause ,Antioxidants ,Superoxide dismutase ,Lipid peroxidation ,chemistry.chemical_compound ,Superoxides ,Carcinoma, Non-Small-Cell Lung ,Malondialdehyde ,DNA-(Apurinic or Apyrimidinic Site) Lyase ,medicine ,Humans ,Lung cancer ,Aged ,biology ,Superoxide Dismutase ,Superoxide ,Cancer ,Extracellular Fluid ,Middle Aged ,Catalase ,medicine.disease ,respiratory tract diseases ,Oncology ,chemistry ,biology.protein ,Cancer research ,Adenocarcinoma ,Lipid Peroxidation ,Oxidative stress - Abstract
Summary Purpose Apurinic/apyrimidinic endonuclease1/ref-1(APE1/ref-1) is a key enzyme in the base excision repair and in transcriptional modulation against oxidative stress. We investigated the altered expression of APE1/ref-1 and antioxidant systems in lung cancer. Patients and methods Tumor specimens from 48 patients with operable non-small cell lung cancer were obtained from 2004 to 2006. Immunohistochemistry, Western blot, lipid peroxidation and superoxide production were performed on the tumor samples and a cultured H460 cell line. Results APE1/ref-1 was mainly localized to the nucleus in the non-tumor regions of the lung cancer tissue specimens. However, nuclear and cytoplasmic expressions of APE1/ref-1 in the lung cancers were markedly up-regulated in the non-small cell lung cancer (NSCLC) specimens including squamous cell and adenocarcinoma specimens. Extracellular superoxide dismutase (ECSOD) and catalase were down-regulated and manganese superoxide dismutase (MnSOD) was up-regulated in the tumor regions of the NSCLC. Tumor regions of the NSCLC showed higher superoxide production and lipid peroxidation levels than non-tumor regions. In the lung adenocarcinoma cell line, H460, treatment with hydrogen peroxide in the presence of a catalase inhibitor, aminotriazole, increased APE1/ref-1 expression, suggesting oxidative stress might have contributed to the induction of APE1/ref-1. Conclusion The results of this study suggest that APE1/ref-1 is up-regulated in the tumor regions of NSCLC. Altered expression of antioxidant systems lead to enhanced production of superoxide production and lipid peroxidation, which can induce APE1/ref-1 in the tumor regions of NSCLS.
- Published
- 2008
50. Tat-APE1/ref-1 protein inhibits TNF-α-induced endothelial cell activation
- Author
-
Hee Kyoung Joo, Jin Bong Park, Sang Ki Lee, Ji-Young Lee, Kwon Ho Lee, Byeong Hwa Jeon, Hyo Shin Kim, Chung-Hyun Cho, and Yun Jeong Song
- Subjects
Tumor Necrosis Factor-alpha ,Biophysics ,Endothelial Cells ,Vascular Cell Adhesion Molecule-1 ,Cell Biology ,Biology ,Vascular endothelial growth inhibitor ,Biochemistry ,DNA-(apurinic or apyrimidinic site) lyase ,Molecular biology ,Monocytes ,Cell biology ,Endothelial stem cell ,Endothelial activation ,Vascular endothelial growth factor A ,Vascular endothelial growth factor C ,Gene Products, tat ,Cell Adhesion ,DNA-(Apurinic or Apyrimidinic Site) Lyase ,Humans ,Tumor necrosis factor alpha ,Cell adhesion ,Molecular Biology ,Cells, Cultured - Abstract
Apurinic/apyrimidinic endonuclease 1/redox factor-1 (APE1/ref-1) is a multifunctional protein involved both in DNA base excision repair and redox regulation. In this study we evaluated the protective role of Tat-mediated APE1/ref-1 transduction on the tumor necrosis factor (TNF)-alpha-activated endothelial activation in cultured human umbilical vein endothelial cells. To construct Tat-APE1/ref-1 fusion protein, human full length of APE1/ref-1 was fused with Tat-protein transduction domain. Purified Tat-APE1/ref-1 fusion protein efficiently transduced cultured endothelial cells in a dose-dependent manner and reached maximum expression at 1h after incubation. Transduced Tat-APE1/ref-1 showed inhibitory activity on the TNF-alpha-induced monocyte adhesion and vascular cell adhesion molecule-1 expression in cultured endothelial cells. These results suggest Tat-APE1/ref-1 might be useful to reduce vascular endothelial activation or vascular inflammatory disorders.
- Published
- 2008
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.